DYAI 200
Alternative Names: DYAI-200Latest Information Update: 20 Apr 2023
At a glance
- Originator Dyadic International
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Influenza virus infections
Most Recent Events
- 18 Apr 2023 Dyadic has a patent covering for the development and manufacture of seasonal and pandemic influenza vaccines from the company's C1 protein production platform
- 10 Nov 2022 DYAI 200 is available for licensing as of 10 Nov 2022. https://www.dyadic.com/about/the-dyadic-story/ (Dyadic International pipeline, November 2022)
- 10 Nov 2022 Preclinical trials in Influenza virus infections in USA (Intradermal) as of November 2022